Zusammenfassung
Einleitung
In den letzten Jahren wird die Früherkennung rheumatologischer Erkrankungen zunehmend wichtiger. Dies trifft insbesondere auch für die inflammatorischen Myopathien zu, die als Multisystemerkrankungen mit Beteiligung innerer Organe durch eine hohe Morbidität und Mortalität gekennzeichnet sind. Eine frühe Diagnosestellung vor Entwicklung irreversibler Organmanifestationen ist daher von großer Bedeutung.
Methoden
Der vorliegende Beitrag erläutert Frühzeichen der Dermatomyositis (DM) und des Antisynthetase-Syndroms und diskutiert Screeningmethoden, die eine frühe Diagnosestellung auch hinsichtlich einer Beteiligung innerer Organe erlauben. Darüber hinaus werden klinisch-serologische Subtypen und deren Bedeutung für die Prognoseabschätzung beschrieben.
Abstract
Introduction
The early diagnosis of rheumatic diseases is becoming increasingly important. This particularly includes inflammatory myopathies which are multisystemic disorders with visceral involvement that are associated with high morbidity and mortality. Early diagnosis before the development of irreversible organ involvement is, therefore, of great importance.
Methods
This report provides information on early signs and symptoms of dermatomyositis and antisynthetase syndrome. Furthermore, screening methods which allow early diagnosis including involvement of internal organs are discussed. In addition, clinical and serological subtypes and their impact on prognosis are described.
Literatur
Bodolay E, Csiki Z, Szekanecz Z et al (2003) Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol 21(3):313–320
Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344–347
Griggs RC, Askanas V, DiMauro S et al (1995) Inclusion body myositis and myopathies. Ann Neurol 38(5):705–713
Marie I (2012) Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep 14(3):275–285
Katzap E, Barilla-LaBarca ML, Marder G (2011) Antisynthetase syndrome. Curr Rheumatol Rep 13(3):175–181
Oh TH, Brumfield KA, Hoskin TL et al (2007) Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc 82(4):441–447
Fathi M, Dastmalchi M, Rasmussen E et al (2004) Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 63(3):297–301
Gupta R, Wayangankar SA, Targoff IN, Hennebry TA (2011) Clinical cardiac involvement in idiopathic inflammatory myopathies: a systematic review. Int J Cardiol 148(3):261–270
Kalluri M, Oddis CV (2010) Pulmonary manifestations of the idiopathic inflammatory myopathies. Clin Chest Med 31(3):501–512
Yoshifuji H, Fujii T, Kobayashi S et al (2006) Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 39(3):233–241
Sato S, Kuwana M (2010) Clinically amyopathic dermatomyositis. Curr Opin Rheumatol 22(6):639–643
Rockerbie NR, Woo TY, Callen JP, Giustina T (1989) Cutaneous changes of dermatomyositis precede muscle weakness. J Am Acad Dermatol 20(4):629–632
Dugan EM, Huber AM, Miller FW, Rider LG (2009) Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol Online J 15(2):1
Dugan EM, Huber AM, Miller FW, Rider LG (2009) Review of the classification and assessment of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol Online J 15(2):2
Rider LG, Werth VP, Huber AM et al (2011) Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken) 63(Suppl 11):S118–S157
Rider LG, Koziol D, Giannini EH et al (2010) Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) 62(4):465–472
Alexanderson H, Broman L, Tollback A et al (2006) Functional index-2: validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis. Arthritis Rheum 55(1):114–122
Agarwal S, Kiely PD (2006) Two simple, reliable and valid tests of proximal muscle function, and their application to the management of idiopathic inflammatory myositis. Rheumatology (Oxford) 45(7):874–879
Ghirardello A, Bassi N, Palma L et al (2013) Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep 15(6):335
Shen H, Xia L, Lu J, Xiao W (2011) Interleukin-17 and interleukin-23 in patients with polymyositis and dermatomyositis. Scand J Rheumatol 40(3):217–220
Mercer LK, Moore TL, Chinoy H et al (2010) Quantitative nailfold video capillaroscopy in patients with idiopathic inflammatory myopathy. Rheumatology (Oxford) 49(9):1699–1705
Degardin A, Morillon D, Lacour A et al (2010) Morphologic imaging in muscular dystrophies and inflammatory myopathies. Skeletal Radiol 39(12):1219–1227
Blijham PJ, Hengstman GJ, Ter Laak HJ et al (2004) Muscle-fiber conduction velocity and electromyography as diagnostic tools in patients with suspected inflammatory myopathy: a prospective study. Muscle Nerve 29(1):46–50
Fredericks EJ (1994) Electromyography in polymyositis and dermatomyositis. Muscle Nerve 17(10):1235–1236
Paganoni S, Amato A (2013) Electrodiagnostic evaluation of myopathies. Phys Med Rehabil Clin N Am 24(1):193–207
Dalakas MC (2012) Pathogenesis and therapies of immune-mediated myopathies. Autoimmun Rev 11(3):203–206
Mozaffar T, Pestronk A (2000) Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres. J Neurol Neurosurg Psychiatry 68(4):472–478
Grundtman C, Bruton J, Yamada T et al (2010) Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies. FASEB J 24(2):570–578
Connors GR, Christopher-Stine L, Oddis CV, Danoff SK (2010) Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest 138(6):1464–1474
Suliman YA HD, Nguyen-Kim TDL, Maurer B et al (2013) High rate of false negatives in the early detection of interstitial lung disease associated with systemic sclerosis by pulmonary function tests. Ann Rheum Dis 72:S3,500–501 2013
Lynch DA, Travis WD, Muller NL et al (2005) Idiopathic interstitial pneumonias: CT features. Radiology 236(1):10–21
Winklehner A, Berger N, Maurer B et al (2012) Screening for interstitial lung disease in systemic sclerosis: the diagnostic accuracy of HRCT image series with high increment and reduced number of slices. Ann Rheum Dis 71(4):549–552
Fathi M, Barbasso Helmers S, Lundberg IE (2012) KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis. J Intern Med 271(6):589–597
Buchbinder R, Forbes A, Hall S et al (2001) Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 134(12):1087–1095
Einhaltung ethischer Richtlinien
Interessenkonflikt. B. Maurer gibt an, dass kein Interessenskonflikt besteht.
Dieser Beitrag enthält keine Studien an Menschen oder Tieren.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Maurer, B. Frühsymptome der Dermatomyositis und des Antisynthetase-Syndroms. Z. Rheumatol. 72, 970–976 (2013). https://doi.org/10.1007/s00393-013-1196-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-013-1196-8